With the arrival of Omicron and the looming threat of other emerging variants of concern, the crucial question on everyone’s mind is: how long does immunity to SARS-CoV-2 last? The evidence will be essential to plan for, and mitigate, future waves of infection and keep the population safe.
As a safe and effective COVID-19 vaccine is now available for school-aged children, it is important to reflect on the multiple streams of benefits arising from their rapid roll-out. Successful immunization campaigns protect children from severe disease, help lower community transmission of the virus, allow the re-establishment of social networks, see the continuance of in-class schooling, and permit the full resumption of extra-curricular activities.
In this Canadian study published in JAMA, researchers wanted to know if the type of information provided about a vaccine could affect people’s likelihood of accepting it.
Long COVID is an emerging phenomenon that is not yet fully understood or well defined.
No, pandemics do not last forever. In this article published in Immunity, the authors provide a description of the epidemiological and immunological measures that underlie the transition from a pandemic state to an endemic state.
Rising COVID-19 cases spurred by the highly transmissible Delta variant have led policymakers and researchers to consider the need for vaccine booster doses.
On September 20th, 2021, Pfizer-BioNtech announced preliminary results from its phase 2/3 trial in children ages 5 to 11 with a two-dose vaccine scheme.
COVID-19 vaccines are effective at preventing hospitalizations and emergency department visits caused by the Delta variant, according to several recent publications.
People infected with SARS-CoV-2 can experience a wide range of outcomes, ranging from asymptomatic infection to severe disease and death.
The proportion of people in the U.S. with SARS-CoV-2 antibodies remains uncertain. A new study published in JAMA used a sample of 1.44 million blood samples from July 2020 through May 2021 to estimate the SARS-CoV-2 seroprevalence in the general US population aged 16 years and older.